Literature DB >> 18180907

Juvenile rats in the forced-swim test model the human response to antidepressant treatment for pediatric depression.

Abbey L Reed1, H Kevin Happe, Frederick Petty, David B Bylund.   

Abstract

RATIONALE: Currently, there are limited treatment options for major depressive disorder in children and adolescents compared to the options available for adults. Many effective treatments used for adult depression, such as the tricyclic antidepressants, lack efficacy when given to children and adolescents.
OBJECTIVE: To more quickly identify compounds that could be effective for treating childhood and adolescent depression, a reliable preclinical animal behavioral test of antidepressant efficacy for pediatric depression is needed. The forced-swim test (FST) with juvenile rats was assessed to determine its reliability as a predictive model for pediatric depression.
MATERIALS AND METHODS: We adapted procedures from the adult FST to test 21-day-old juvenile rats. The 21-day-old animals were treated with three classes of antidepressant drugs before being assessed in the FST: the selective serotonin reuptake inhibitors escitalopram or fluoxetine; the tricyclic antidepressants desipramine or imipramine; and the monoamine oxidase inhibitor tranylcypromine.
RESULTS: The 21-day-old rats showed dose-dependent changes in behaviors similar to those seen in adults when treated with escitalopram or fluoxetine. Tranylcypromine also decreased immobility in 21-day-old rats. Treatment with desipramine or imipramine, however, was not effective at reducing immobility in the 21-day-old rats.
CONCLUSIONS: The juvenile FST accurately predicts the efficacy of selective serotonin reuptake inhibitors and the lack of efficacy of tricyclic antidepressants in the treatment of depression in children and adolescents. This suggests that the FST using 21-day-old rats may help to develop better treatments for childhood and adolescent depression.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18180907     DOI: 10.1007/s00213-007-1052-0

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  49 in total

Review 1.  Stress, norepinephrine and depression.

Authors:  B E Leonard
Journal:  J Psychiatry Neurosci       Date:  2001       Impact factor: 6.186

Review 2.  Distinguishing roles for norepinephrine and serotonin in the behavioral effects of antidepressant drugs.

Authors:  Irwin Lucki; Olivia F O'Leary
Journal:  J Clin Psychiatry       Date:  2004       Impact factor: 4.384

Review 3.  Should we use antidepressant medications for children and adolescents with depressive disorders?

Authors:  B Birmaher
Journal:  Psychopharmacol Bull       Date:  1998

4.  Neonatal antidepressant exposure has lasting effects on behavior and serotonin circuitry.

Authors:  Dorota Maciag; Kimberly L Simpson; David Coppinger; Yuefeng Lu; Yue Wang; Rick C S Lin; Ian A Paul
Journal:  Neuropsychopharmacology       Date:  2006-01       Impact factor: 7.853

5.  Action of serotoninmimetics in the behavioral despair test in rats.

Authors:  Z Górka; E Wojtasik; H Kwiatek; J Maj
Journal:  Commun Psychopharmacol       Date:  1979

6.  Antidepressant-like behavioral effects mediated by 5-Hydroxytryptamine(2C) receptors.

Authors:  J F Cryan; I Lucki
Journal:  J Pharmacol Exp Ther       Date:  2000-12       Impact factor: 4.030

7.  Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial.

Authors:  John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe
Journal:  JAMA       Date:  2004-08-18       Impact factor: 56.272

8.  Children with prepubertal-onset major depressive disorder and anxiety grown up.

Authors:  M M Weissman; S Wolk; P Wickramaratne; R B Goldstein; P Adams; S Greenwald; N D Ryan; R E Dahl; D Steinberg
Journal:  Arch Gen Psychiatry       Date:  1999-09

9.  Pharmacokinetically designed double-blind placebo-controlled study of nortriptyline in 6- to 12-year-olds with major depressive disorder.

Authors:  B Geller; T B Cooper; D L Graham; H H Fetner; F A Marsteller; J M Wells
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  1992-01       Impact factor: 8.829

10.  The effects of combined treatment with MK-801 and antidepressant drugs in the forced swimming test in rats.

Authors:  J Maj; Z Rogóz; G Skuza
Journal:  Pol J Pharmacol Pharm       Date:  1992 May-Jun
View more
  23 in total

1.  Effects of neonatal flutamide treatment on hippocampal neurogenesis and synaptogenesis correlate with depression-like behaviors in preadolescent male rats.

Authors:  J M Zhang; L Tonelli; W T Regenold; M M McCarthy
Journal:  Neuroscience       Date:  2010-04-21       Impact factor: 3.590

2.  Juvenile administration of concomitant methylphenidate and fluoxetine alters behavioral reactivity to reward- and mood-related stimuli and disrupts ventral tegmental area gene expression in adulthood.

Authors:  Brandon L Warren; Sergio D Iñiguez; Lyonna F Alcantara; Katherine N Wright; Eric M Parise; Sarah K Weakley; Carlos A Bolaños-Guzmán
Journal:  J Neurosci       Date:  2011-07-13       Impact factor: 6.167

3.  Robust presynaptic serotonin 5-HT(1B) receptor inhibition of the striatonigral output and its sensitization by chronic fluoxetine treatment.

Authors:  Shengyuan Ding; Li Li; Fu-Ming Zhou
Journal:  J Neurophysiol       Date:  2015-03-18       Impact factor: 2.714

Review 4.  Ontogeny and regulation of the serotonin transporter: providing insights into human disorders.

Authors:  Lynette C Daws; Georgianna G Gould
Journal:  Pharmacol Ther       Date:  2011-04-05       Impact factor: 12.310

5.  Ontogeny of Norepinephrine Transporter Expression and Antidepressant-Like Response to Desipramine in Wild-Type and Serotonin Transporter Mutant Mice.

Authors:  Nathan C Mitchell; Melodi A Bowman; Georgianna G Gould; Wouter Koek; Lynette C Daws
Journal:  J Pharmacol Exp Ther       Date:  2016-11-09       Impact factor: 4.030

6.  Repeated Forced Swim Exacerbates Methamphetamine-Induced Neurotoxicity: Neuroprotective Effects of Nanowired Delivery of 5-HT3-Receptor Antagonist Ondansetron.

Authors:  José Vicente Lafuente; Aruna Sharma; Dafin F Muresanu; Asya Ozkizilcik; Z Ryan Tian; Ranjana Patnaik; Hari S Sharma
Journal:  Mol Neurobiol       Date:  2018-01       Impact factor: 5.590

7.  Fluoxetine exposure during adolescence alters responses to aversive stimuli in adulthood.

Authors:  Sergio D Iñiguez; Lyonna F Alcantara; Brandon L Warren; Lace M Riggs; Eric M Parise; Vincent Vialou; Katherine N Wright; Genesis Dayrit; Steven J Nieto; Matthew B Wilkinson; Mary K Lobo; Rachael L Neve; Eric J Nestler; Carlos A Bolaños-Guzmán
Journal:  J Neurosci       Date:  2014-01-15       Impact factor: 6.167

8.  Antidepressant-like effects and basal immobility depend on age and serotonin transporter genotype.

Authors:  Wouter Koek; Lynette C Daws; Nathan C Mitchell
Journal:  Genes Brain Behav       Date:  2015-09       Impact factor: 3.449

9.  Treatment with escitalopram but not desipramine decreases escape latency times in a learned helplessness model using juvenile rats.

Authors:  Abbey L Reed; Jeffrey C Anderson; David B Bylund; Frederick Petty; Hesham El Refaey; H Kevin Happe
Journal:  Psychopharmacology (Berl)       Date:  2009-04-22       Impact factor: 4.530

Review 10.  Childhood and adolescent depression: why do children and adults respond differently to antidepressant drugs?

Authors:  David B Bylund; Abbey L Reed
Journal:  Neurochem Int       Date:  2007-06-30       Impact factor: 3.921

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.